1. Home
  2. SPRB vs IMNN Comparison

SPRB vs IMNN Comparison

Compare SPRB & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRB
  • IMNN
  • Stock Information
  • Founded
  • SPRB 2014
  • IMNN 1982
  • Country
  • SPRB United States
  • IMNN United States
  • Employees
  • SPRB N/A
  • IMNN N/A
  • Industry
  • SPRB Medicinal Chemicals and Botanical Products
  • IMNN Biotechnology: Pharmaceutical Preparations
  • Sector
  • SPRB Health Care
  • IMNN Health Care
  • Exchange
  • SPRB Nasdaq
  • IMNN Nasdaq
  • Market Cap
  • SPRB 15.7M
  • IMNN 13.6M
  • IPO Year
  • SPRB 2020
  • IMNN 1985
  • Fundamental
  • Price
  • SPRB $0.33
  • IMNN $0.88
  • Analyst Decision
  • SPRB Hold
  • IMNN Strong Buy
  • Analyst Count
  • SPRB 7
  • IMNN 2
  • Target Price
  • SPRB $2.17
  • IMNN $20.50
  • AVG Volume (30 Days)
  • SPRB 300.3K
  • IMNN 141.9K
  • Earning Date
  • SPRB 03-21-2025
  • IMNN 05-12-2025
  • Dividend Yield
  • SPRB N/A
  • IMNN N/A
  • EPS Growth
  • SPRB N/A
  • IMNN N/A
  • EPS
  • SPRB N/A
  • IMNN N/A
  • Revenue
  • SPRB $7,101,000.00
  • IMNN N/A
  • Revenue This Year
  • SPRB N/A
  • IMNN N/A
  • Revenue Next Year
  • SPRB N/A
  • IMNN N/A
  • P/E Ratio
  • SPRB N/A
  • IMNN N/A
  • Revenue Growth
  • SPRB N/A
  • IMNN N/A
  • 52 Week Low
  • SPRB $0.33
  • IMNN $0.64
  • 52 Week High
  • SPRB $1.29
  • IMNN $3.65
  • Technical
  • Relative Strength Index (RSI)
  • SPRB 27.09
  • IMNN 49.35
  • Support Level
  • SPRB $0.34
  • IMNN $0.86
  • Resistance Level
  • SPRB $0.36
  • IMNN $0.93
  • Average True Range (ATR)
  • SPRB 0.03
  • IMNN 0.05
  • MACD
  • SPRB -0.01
  • IMNN 0.00
  • Stochastic Oscillator
  • SPRB 2.70
  • IMNN 61.00

About SPRB Spruce Biosciences Inc.

Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).

About IMNN Imunon Inc.

Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.

Share on Social Networks: